First, Big Pharma will start taking small positions in these tiny startup “psychedelic” companies. They’ll read the writing on the wall, as positive results from Phase III clinical trials for the treatment depression roll in. I call this the “foot in the door.”
Next, the FDA will start approving psychedelic therapies. The agency issued its first draft guidance on clinical trials using psychedelic drugs in June 2023. Sidenote: When that happened, the stock we’re looking at today shot 75% higher in a month. That was just a test, and there’s more to come.
Finally, after those approvals start, Big Pharma will step in to buy as many “assets” in the space to ensure that this new age treatment doesn’t bury their “old school” patented and exclusive drugs.
I’m not the only one that’s reading this playbook.
This post appeared first on MoneyMorning.com.